Clinical trial · Interventional
Radiotherapy - Cerebrovascular Reactivity (RT-CVR Study)
MRI Changes With Administered Oxygen and Carbon Dioxide in Patients With Brain Tumors Receiving Radiotherapy: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Brain tumours often have low oxygen levels, and that makes them more resistant to radiation therapy. If patients breathe the right mixture of oxygen during treatment, radiation may work better. In this study, patients with brain tumour will undergo a special MRI test while they breathe different mixtures of oxygen and carbon dioxide to find out whether oxygen levels improve in the tumor. Patients will also be asked to repeat this MRI test during the second week of radiation therapy, as well as 3 months, 6 months and 1 year after RT. The MRI test after RT will help us understand how the blood vessels in the normal brain are affected by radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MRI for brain mets
- interventionNames
- Procedure: MRI
Primary outcomes (1)
- measure
- - To measure the inter-patient variability of change in tumour oxygenation with carbogen adminstration using MRI
- timeFrame
- 2 years
Secondary outcomes (4)
- measure
- - To determine whether modulation of oxygen and carbon dioxide administration can improve tumour oxygenation relative to standard carbogen breathing on MRI
- timeFrame
- 2 years
- measure
- - To determine whether changes in tumour oxygenation with carbogen administration are different during the second week of radiotherapy compared to baseline measurements
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with primary gliomas visible on MRI who are planning to receive radiotherapy or * Patients with brain metastases\>1cm who are planning to receive radiotherapy * Karnofsky Performance Status \>60 * Age 18 years * Patients must be willing to visit Toronto Western Hospital for at least one MRI scan prior radiotherapy Exclusion Criteria: * Seizures not controlled with medications, or non compliance with prescribed anti-seizure medication * Prior radiation therapy to the brain * Pregnancy * Unwilling or unable to co-operate with breathing maneuvers * Respiratory or cardiac limitations to breathing at 20 L/min * Medical contra-indications to limited hypercapnia or hypocapnia (known increased intracerebral pressure, metabolic acidosis or alkalosis) * Contraindication to MRI (patients weighing\>136 kgs-weight limit for the scanner tables; allergy to MR contrast agent; patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI) * Other medical conditions deemed by the PI or associates to make the patients ineligible for protocol procedures
References
Publications (0)
Data not yet available